ストックスクリーナーアプリを入手
3.28
8.38%
-0.30
アフターアワーズ：
3.40
0.12
+3.66%
前日終値:
$3.58
開ける：
$3.54
24時間の取引高:
65,857
Relative Volume:
0.62
時価総額：
$4.92M
収益：
当期純損益:
$-28.53M
株価収益率:
-1.8422
EPS:
-1.7805
ネットキャッシュフロー:
$-20.10M
1週間 パフォーマンス:
-58.79%
1か月 パフォーマンス:
-59.66%
6か月 パフォーマンス:
-83.68%
1年 パフォーマンス:
-97.17%
1日の値動き範囲:
$3.14
$3.6748
1週間の範囲:
$3.14
$5.775
52週間の値動き範囲:
$1.865
$139.00
Medicus Pharma Ltd Stock (MDCX) Company Profile
名前
Medicus Pharma Ltd
セクター
電話
610-540-7515
住所
300 CONSHOHOCKEN STATE RD., W. CONSHOHOCKEN
Compare MDCX vs LLY, JNJ, ABBV, MRK, NVS
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
MDCX
Medicus Pharma Ltd
|
3.28 | 4.92M | 0 | -28.53M | -20.10M | -1.7805 |
LLY
Lilly Eli Co
|
1,166.51 | 1.04T | 72.25B | 25.28B | 10.37B | 27.78 |
JNJ
Johnson Johnson
|
248.61 | 599.12B | 97.93B | 21.04B | 17.80B | 8.6278 |
ABBV
Abbvie Inc
|
274.36 | 484.83B | 62.82B | 3.60B | 19.98B | 2.0274 |
MRK
Merck Co Inc
|
141.98 | 350.29B | 65.51B | 8.93B | 14.12B | 3.5532 |
NVS
Novartis Ag Adr
|
142.41 | 270.68B | 54.66B | 13.58B | 16.05B | 7.0171 |
Medicus Pharma Ltd (MDCX) 最新ニュース
The FDA authorized a planned skin-cancer study for people with a rare inherited condition. - Stock Titan
Medicus Pharma (MDCX) Shares Fall 24% After Hours: Here's Why - Benzinga
Medicus Pharma to implement 50-for-1 share consolidation to meet Nasdaq minimum bid - TradingView
Medicus Pharma to execute 50-to-1 reverse stock split on Oct. 12 - StreetInsider
Medicus Pharma Ltd. Warrant (MDCXW) Holds Flat at $0.35 Inside a Narrow Trading BandMACD Signal Stocks - https://www.dars.gov.et/
Medicus Pharma Ltd. (MDCX) Stock Price, News, Quote & History - Yahoo! Finance Canada
Dr. Raza Bokhari Discloses Investment at Medicus Pharma Ltd. with 5.3% Stake - TradingView
Medicus Pharma ends standby equity purchase agreement with Yorkville - Investing.com
How big is Medicus Pharma (MDCX) CEO Raza Bokhari's stake? - Stock Titan
MDCX 8-K FilingsMedicus Pharma Ltd. SEC 8-K - Stock Titan
FDA Clears Medicus SkinJect Study for Gorlin Syndrome - MyChesCo
Inside the deal: How a Montco biotech secured a Pfizer drug candidate - The Business Journals
Form 8K Medicus Pharma Ltd For: 11 September By Investing.com - Investing.com Nigeria
Medicus Pharma officers receive restricted shares in lieu of cash bonuses - Investing.com Nigeria
Medicus Pharma officers receive restricted shares in lieu of cash bonuses - Investing.com India
Medicus Pharma officers receive restricted shares in lieu of cash bonuses - Investing.com
Form 8K Medicus Pharma Ltd For: 11 September By Investing.com - Investing.com India
Medicus Pharma officers receive restricted shares in lieu of cash bonuses - Investing.com UK
Medicus Pharma officers receive restricted shares in lieu of cash bonuses - Investing.com
Medicus Pharma posts phase 2 study results for skin cancer drug By Investing.com - Investing.com Australia
Medicus Pharma officers receive restricted shares in lieu of cash bonuses By Investing.com - Investing.com South Africa
Medicus Pharma posts phase 2 study results for skin cancer drug - Investing.com Nigeria
Medicus Pharma secures Pfizer ADC deal, advances SkinJect and precision oncology strategy - Proactive financial news
Medicus Pharma secures Pfizer ADC deal, advances SkinJect and precision oncology strategy - Yahoo Finance
Medicus Pharma Identifies 200 µg SkinJect Patch as Lead Development Dose After Phase 2 Study - Yahoo Finance
Conshohocken's Medicus Pharma Picks Up a Discarded Pfizer Cancer Drug in a Deal Worth More Than $1 Billion - BioBuzz
Medicus Pharma posts phase 2 study results for skin cancer drug - Investing.com India
Medicus Pharma posts phase 2 study results for skin cancer drug - Investing.com Canada
Medicus Pharma Ltd. Posts Abridged Phase 2 Clinical Study Report for SkinJect® SKNJCT-003, Advances Gorlin Syndrome Development Plan - Quiver Quantitative
Medicus Pharma posts phase 2 study results for skin cancer drug - Investing.com UK
FDA authorizes the next study of a skin cancer patch - Stock Titan
Medicus Pharma Advances Transformation into a Precision Oncology-Led Biotechnology Company - BioBuzz
Medicus Pharma reports positive Phase 2 data for SkinJect in skin cancer treatment - Proactive financial news
Medicus Pharma (MDCX) grants COO 735K shares and options - Stock Titan
Medicus Pharma (NASDAQ: MDCX) awards stock and options to its chief medical officer - stocktitan.net
Medicus Pharma (MDCX) hands CSO 588K shares and 100K options - stocktitan.net
Medicus Pharma (MDCX) CEO adds millions of shares and options in 2026 grant - Stock Titan
CFO adds Medicus Pharma (MDCX) stock and options - stocktitan.net
Medicus Pharma Prioritises CD228V Oncology Programme in Development Strategy - Yahoo Finance
Medicus Pharma shifts focus to precision oncology with CD228V By Investing.com - Investing.com Nigeria
Medicus Pharma shifts focus to precision oncology with CD228V - Investing.com
Medicus Pharma shifts focus to precision oncology with CD228V By Investing.com - Investing.com UK
Medicus Pharma Ltd. Repositions as Precision Oncology-Led Biotech, Prioritizes CD228V, SkinJect and Teverelix Programs - Quiver Quantitative
Medicus Pharma Advances Transformation into a Precision Oncology-Led Biotechnology Company - Yahoo Finance
Medicus Pharma reorients around new cancer drug candidate, sharpens focus for other programs - Proactive financial news
New to The Street's Show #753 Airs Nationwide on Bloomberg Television Across the U.S., MENA and Latin America Featuring FreeCast (NASDAQ:CAST), Stardust Power (NASDAQ:SDST), Lost Soldier Oil and Gas, Virtuix Holdings (NASDAQ:VTIX), and Medi - ACCESS Newswire
Price to sales forward of Medicus Pharma Ltd. – NASDAQ:MDCXW - TradingView
Pfizer hands former Seagen ADC to Medicus in USD 1b-plus deal - AllSci
Pfizer Licenses Discontinued Cancer Drug to Medicus Pharma in Deal Valued Over $1 Billion - finance.biggo.com
Medicus Pharma Inks Global Licensing Deal with Pfizer Worth Over $1 Billion - Benzinga
Medicus Pharma Ltd (MDCX) 財務データ
収益
当期純利益
現金流量
EPS
2.86%
5.53%
大文字化:
|
ボリューム (24 時間):